Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BMY 
Bristol-Myers Squibb Company (BMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: BMY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
27 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $53.14
1 Year Target Price $53.14
| 4 | Strong Buy |
| 4 | Buy |
| 18 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.9% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 93.79B USD | Price to earnings Ratio 15.51 | 1Y Target Price 53.14 |
Price to earnings Ratio 15.51 | 1Y Target Price 53.14 | ||
Volume (30-day avg) 27 | Beta 0.34 | 52 Weeks Range 42.38 - 61.00 | Updated Date 11/2/2025 |
52 Weeks Range 42.38 - 61.00 | Updated Date 11/2/2025 | ||
Dividends yield (FY) 5.44% | Basic EPS (TTM) 2.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When Before Market | Estimate 1.69 | Actual 1.63 |
Profitability
Profit Margin 12.57% | Operating Margin (TTM) 31.57% |
Management Effectiveness
Return on Assets (TTM) 9.39% | Return on Equity (TTM) 33.78% |
Valuation
Trailing PE 15.51 | Forward PE 7.58 | Enterprise Value 130406480871 | Price to Sales(TTM) 1.95 |
Enterprise Value 130406480871 | Price to Sales(TTM) 1.95 | ||
Enterprise Value to Revenue 2.73 | Enterprise Value to EBITDA 8.65 | Shares Outstanding 2035753027 | Shares Floating 2032129387 |
Shares Outstanding 2035753027 | Shares Floating 2032129387 | ||
Percent Insiders 0.07 | Percent Institutions 82.93 |
Upturn AI SWOT
Bristol-Myers Squibb Company
Company Overview
History and Background
Bristol-Myers Squibb (BMS) was formed in 1989 through the merger of Bristol-Myers and Squibb Corporation. Bristol-Myers was founded in 1887 and Squibb in 1858. BMS has grown through internal development and acquisitions, focusing on biopharmaceuticals.
Core Business Areas
- Oncology: Develops and markets therapies for various cancers, including solid tumors and hematologic malignancies.
- Hematology: Focuses on treatments for blood disorders and related conditions.
- Immunology: Develops therapies for autoimmune diseases and other immune-related disorders.
- Cardiovascular: Develops and markets treatments for cardiovascular diseases.
Leadership and Structure
The CEO is Christopher Boerner. The company operates with a functional structure, with divisions focused on research and development, commercialization, and manufacturing.
Top Products and Market Share
Key Offerings
- Opdivo: A PD-1 immune checkpoint inhibitor used to treat various cancers. Competitors include Keytruda (Merck) and other PD-1/PD-L1 inhibitors. Opdivo global revenue in 2023 was $9.04 billion.
- Eliquis: An anticoagulant used to prevent blood clots in patients with atrial fibrillation and other conditions. Competitors include Xarelto (Bayer/Johnson & Johnson) and other direct oral anticoagulants (DOACs). Eliquis global revenue in 2023 was $12.2 billion.
- Revlimid: Used to treat multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Revlimid sales have declined after losing exclusivity. Competitors include generics of Revlimid and other treatments for multiple myeloma. Revlimid global revenue in 2023 was $6.03 billion.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. It's driven by innovation and the need for new treatments for unmet medical needs.
Positioning
BMS is a major player in the biopharmaceutical industry, with a strong focus on oncology, immunology, and cardiovascular diseases. It competes with other large pharmaceutical companies and biotech firms.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1.4 trillion. BMS is positioned to capture a significant portion of this TAM with its diverse portfolio and strong presence in key therapeutic areas.
Upturn SWOT Analysis
Strengths
- Strong portfolio of marketed products
- Robust pipeline of new drugs
- Established global presence
- Expertise in oncology, immunology, and cardiovascular diseases
Weaknesses
- Reliance on key products with patent expirations
- High debt level from acquisitions
- Integration challenges from acquisitions
- Exposure to biosimilar competition
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Development of innovative therapies
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- PFE
- ABBV
- JNJ
Competitive Landscape
BMS competes with other large pharmaceutical companies and biotech firms. Its competitive advantages include its strong portfolio of marketed products and its robust pipeline of new drugs. Its disadvantages include its reliance on key products with patent expirations and its high debt level.
Major Acquisitions
Karuna Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 14000
- Strategic Rationale: Acquisition to expand into neuroscience and add KarXT to its portfolio, a potential blockbuster treatment for schizophrenia.
Celgene
- Year: 2019
- Acquisition Price (USD millions): 74000
- Strategic Rationale: Expanded BMS's oncology portfolio with Revlimid and other key products, creating a leading biopharmaceutical company.
Growth Trajectory and Initiatives
Historical Growth: BMS has grown through a combination of organic growth and acquisitions. The company's growth has been driven by its key products and expansion into new markets.
Future Projections: Analysts project modest revenue growth for BMS in the coming years, driven by new product launches and expansion of existing products. Earnings growth is expected to be higher due to cost savings and improved margins.
Recent Initiatives: Recent initiatives include the acquisition of Karuna Therapeutics to expand into neuroscience, and the launch of new products such as Augtyro.
Summary
Bristol-Myers Squibb is a major biopharmaceutical company with a strong oncology focus. Its strengths lie in its established portfolio and pipeline, while weaknesses include patent expirations and debt. Recent acquisitions provide future growth opportunities. Investors should monitor debt levels and competitive pressures.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Bristol-Myers Squibb Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change. Consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bristol-Myers Squibb Company
Exchange NYSE | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1972-01-01 | CEO & Chairman Dr. Christopher S. Boerner Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 34100 | Website https://www.bms.com |
Full time employees 34100 | Website https://www.bms.com | ||
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.